TRENDING :  Market Movers  |  Top 50   AAPL (-0.57%)    TSLA (-3.75%)    TVIX (1.55%)    QURE (2.34%)    QQQ (-0.37%)    QCOM (-0.2%)    PSTG (1.46%)    PEI (-1.96%)    PAH (0%)    MCD (1.29%)    KO (1.69%)    JPM (-0.21%)    IVC (-7.29%)    IMDZ (309.86%)    GS (-1.13%)    GOOGL (-1.47%)    FUV (-2.18%)    FDX (0.21%)    FCEL (-34.08%)    FB (-1.56%)    EA (-1.8%)    CRM (0.69%)    CBS (-0.55%)    BILI (-0.93%)    BIDU (0.37%)

 AVEO - AVEO Pharmaceuticals

$0.63 [0.01][1.42%]

Next Earnings

3/12/2019

BMO

Recommend
Trade Idea »



ANALYST RATINGS

Quarterly Rating Chart
Rating

2


1=Strong Buy, 2=Buy, 3=Hold, 4=Underperform, 5=Sell
Price Targets
High $3.00
Low $1.00
Average $1.67
Current $0.63

CompanyAnalyst NamePT ActionActionRatingTargetDate
B. Riley FBRLowersDowngradesHold$1.0002/04/19
H.C. WainwrightLowersDowngradesHold$1.0002/01/19
BairdAnnouncesInitiates Coverage OnStrong Buy$3.0001/04/19
*Last 90 days

OPEN RECOMMENDATIONS

No recommendations found.


This list is limited to recommendations made in last 7 days only. Subscribe to a service to see all their recommendations.

TRADERS TRACKING $AVEO

TRENDING ARTICLES



The Zacks Analyst Blog Highlights: Gilead, Vertex, Celgene, Alkermes and AVEO

02/07/19
For Immediate Release Chicago IL February 7 2019 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog

Biotech Stock Roundup: Celgene Tops in Q4, Gilead Disappoints, ALKS & AVEO Sink

02/06/19
Earnings took centerstage for the biotech sector this week with quite a few bigwigs like Gilead Sciences GILD Vertex Pharmaceuticals VRTX and Celgene CELG coming up with fourth quarter results Apart from these regular pipeline updates and data read outs were also in the

Week Ahead In Pharmaceuticals: 6 Stocks To Watch (EOLS, AVRO, SGMO...)

02/01/19
Week Ahead In Pharmaceuticals: 6 Stocks To Watch (EOLS, AVRO, SGMO...)

AVEO Oncology Plunges on Delay in Filing Fotivda NDA With FDA

02/01/19
AVEO Oncology AVEO received a major setback as it had to delay its submission of a new drug application NDA seeking approval for its kidney cancer drug Fotivda tivozanib The company decided not to submit a NDA in the United States after the FDA informed the company that it was

AVEO Crashes, FDA Approves 1st Generic Of ADVAIR DISKUS, 'Tis Advantage TTNP

02/01/19
AVEO Crashes, FDA Approves 1st Generic Of ADVAIR DISKUS, 'Tis Advantage TTNP

Why AVEO Oncology Stock Is Crashing Today

01/31/19
What happened Shares of AVEO Oncology NASDAQ AVEO had crashed 58 6 as of 11 33 a m EST on Thursday The biotech announced that 160 based on preliminary overall survival rate data from its phase 3 Tivo 3 clinical study it wouldn t file for regulatory approval of

Options Traders Expect Huge Moves in AVEO Pharmaceuticals (AVEO) Stock

01/23/19
Investors in AVEO Pharmaceuticals Inc AVEO need to pay close attention to the stock based on moves in the options market lately That is because the Mar 18 2019 2 50 Call had some of the highest implied volatility of all equity options today What is Implied Volatility